A forum for researchers, students and applicants in the field of cyclodextrin technology
This study fabricated a β/γ-CD-MOF composite via β-CD and γ-CD hybridization, incorporating the hydrophobic anti-inflammatory agent atorvastatin, followed by surface
The progression of atherosclerosis (AS) is strongly linked to lipid crystals accumulation caused by cholesterol metabolism disorders and the worsening
Atherosclerosis (AS) has been considered a systemic disease characterized by the excessive generation of reactive oxygen species (ROS) and the
The removal of the toxic oxidized cholesterol, 7-ketocholesterol (7KC), from cells through the administration of therapeutics has the potential to
A review with 402 references Atherosclerosis is a complex cardiovascular disease driven by multiple factors, including aging, inflammation, oxidative stress,
Recently, increasing evidence shows that cyclodextrins have an inhibitory effect against atherosclerosis, a chronic disease inducing atherosclerotic cardiovascular diseases (ASCVDs).
Cyclarity Therapeutics is pleased to announce regulatory approval to begin its first-in-human clinical trial. The trial will be conducted at CMAX,
Cardiovascular diseases are disorders that compromise the heart and circulatory systems. Ischemic heart disease is one of the causes of
Cyclodextrins have long been known as host molecules, a special feature that has led to their widespread use in a
This study sought to systematically compare the efficacy and mechanism of cyclodextrins as drug interventions in lipid metabolism diseases, potentially
